Plain-English translation of NCT04657861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new type of treatment that uses your own immune cells to fight multiple myeloma that has returned or stopped responding to other therapies. Researchers are studying whether this treatment is safe and how well it works. The trial will enroll 36 patients at a single medical center.
Multiple myeloma is a serious blood cancer, and some patients' disease comes back or becomes resistant to standard treatments. This medication is designed to work differently by training immune cells to target cancer cells, offering hope for patients who have limited options.
You likely qualify if…
You likely don't qualify if…
You will receive the treatment through an intravenous infusion (a needle in your vein). The trial is designed to monitor your safety very carefully, as this is an early-stage study. You would need to be evaluated before starting to make sure you meet all health requirements, and then followed closely afterward to watch for any effects from the treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Zhejiang University
Collaborators
Yake Biotechnology Ltd.
Enrollment target
~36 participants
Started
May 2022
Primary completion
August 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang, PhD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.